‘WELL POSITIONED TO CAPTURE MANY MARKET OPPORTUNITIES’

“There is good momentum for new chemical entity and new biological entity approvals by regulators underpinned by a strong pipeline of drugs in early stages of discovery and development. The continuing drive to reduce the cost and cycle times associated with drug discovery while driving productivity is expected to increase outsourcing further, with significant interest in the integrated drug discovery and development model. On the manufacturing side, growing demand for biologics, huge capacity consumption from vaccines, the capital-intensive nature of the business, and the complexity involved in biopharmaceutical manufacturing is driving demand for outsourcing. We believe Syngene is well positioned to capture many of these market opportunities.” - MAHESH BHALGAT, Chief Operating Officer, Syngene International, Hyderabad